Lencanizumab plus standard care for early Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether adding a new drug called lencanizumab to standard Alzheimer's medications can help slow memory loss in people with early Alzheimer's. It's an observational study, meaning you'll receive the treatment as part of your regular care, and researchers will track your progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have a diagnosis of early Alzheimer's or mild cognitive impairment, with memory or thinking problems.
- A brain scan or spinal fluid test shows amyloid plaques (a protein linked to Alzheimer's).
- You have a caregiver or family member who can help with study visits.
- You do not have other serious brain conditions (like Parkinson's, stroke, epilepsy) or unstable medical illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.